We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA may have offered struggling AstraZeneca a lifeline, granting a “breakthrough” designation for its cancer immunotherapy Imfinzi in early-stage lung cancer.